Share this post: Created by: Kristin Watson PharmD, BCCP and and Brent N. Reed, PharmD, BCCP Reviewed by: Stormi Gale, PharmD, BCCP Share this post:
Share this post: Created by: Stormi Gale, PharmD, BCCP and Brent N. Reed, PharmD, BCCP Reviewed by: Kristin Watson, PharmD, BCCP Share this post:
Use of oral anticoagulation therapy in patients with liver disease is complex. The risks and benefits of therapy need to be considered as those with liver disease can be at heightended risk of bleeding. This blog post will review the literature surrounding the use of oral anticoagulation in patients with atrial fibrillation and liver disease and recommendations on selecting therapy, if any, will be discussed.
Macrolides and fluoroquinolones (FQs) are two of the most commonly prescribed antibiotics; however, recent studies have revealed that these medications are associated with a higher risk of cardiovascular (CV) adverse events (AEs) including arrhythmias and valvular regurgitation. This blog summarizes recent literature on CV AEs associated with FQs and macrolides and provides recommendations on their use within certain at-risk populations.